Microwave-assisted Sinthesis of Thymyl Ethers and Esters in Aqueous Medium
摘要:
Various thymyl ethers and esters have been synthesized by reactions of thymol with alkyl halides and acid chlorides, respectively, in aqueous medium under environmentally benign conditions using microwave irradiation. The products are important as potent pest managing agents.
[EN] BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT<br/>[FR] DÉRIVÉS BENZIMIDAZOLE EN TANT QUE BLOQUEURS SÉLECTIFS DU COURANT DE SODIUM PERSISTANT
申请人:ALLERGAN INC
公开号:WO2013101926A1
公开(公告)日:2013-07-04
The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R1, R2, R3, R4, R5, m, and n in Formula (I) are as defined herein.
New carvacrol and thymol derivatives as potential insecticides: synthesis, biological activity, computational studies and nanoencapsulation
作者:Carolina M. Natal、Maria José G. Fernandes、Nuno F. S. Pinto、Renato B. Pereira、Tatiana F. Vieira、Ana Rita O. Rodrigues、David M. Pereira、Sérgio F. Sousa、A. Gil Fortes、Elisabete M. S. Castanheira、M. Sameiro T. Gonçalves
DOI:10.1039/d1ra05616f
日期:——
carried out in liposomes of egg phosphatidylcholine/cholesterol (7 : 3) prepared by both thin film hydration and ethanolic injection methods. The compound-loaded liposomes were generally monodisperse and with sizes smaller than or around 200 nm. The thin film hydration method allowed high encapsulation efficiencies (above 85%) for both compounds and a delayed release, while for the systems prepared by ethanolic
BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT
申请人:Allergan, Inc.
公开号:US20130172342A1
公开(公告)日:2013-07-04
The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula I
or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said compound, wherein variables R, R
1
, R
2
, R
3
, R
4
, R
5
, m, and n in Formula I are as defined herein.